Phase II trial of RCH 01 in patients in Japan with pattern baldness

Trial Profile

Phase II trial of RCH 01 in patients in Japan with pattern baldness

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2017

At a glance

  • Drugs RCH 01 (Primary)
  • Indications Male pattern baldness
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shiseido
  • Most Recent Events

    • 05 Jan 2017 According to a RepliCel media release, data from this study anticipated in 2018. Data package created on RCH-01 based on this trial can be used in regulatory submissions and in negotiating the license for this product for the regions outside of Shiseido's exclusive territory.
    • 21 Jul 2016 According to RepliCel media release, this study will be conducted at Tokyo Medical University Hospital and Toho University Ohasi Medical Center, by Drs. Tsuboi and Niiyama and will be financed by Shiseido Company.
    • 21 Jul 2016 According to RepliCel media release, RCH-01 product, for the treatment of androgenetic alopecia, is now cleared by the Japanese regulatory authorities for use.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top